Bluejay Therapeutics
Bluejay Therapeutics, Inc. was a clinical-stage biopharmaceutical company headquartered in Redwood City, California, developing treatments for viral hepatitis and liver disease. Its lead asset, brelovitug (BJT-778), is an investigational monoclonal antibody targeting the surface antigen shared by the hepatitis D and hepatitis B viruses; it received U.S. FDA Breakthrough Therapy designation for chronic hepatitis delta and reported a 100% virologic response at week 48 in its Phase 2 monotherapy study before entering the AZURE-2 global Phase 3 trial. The company also advanced a proprietary TLR9 agonist (cavrotolimod), a liver-targeted HBV transcript inhibitor (BJT-628) and a liver-targeted fatty acid synthase inhibitor (BJT-188) toward a combination regimen aimed at functional cure of chronic hepatitis B. Mirum Pharmaceuticals agreed to acquire Bluejay Therapeutics in December 2025 and completed the acquisition on 26 January 2026; the corporate site now serves a single acquisition notice redirecting readers to mirumpharma.com. Bluejay Therapeutics never ran a developer program — no product API, no developer portal, no API documentation, no SDKs, no GitHub organisation and no package-registry presence. The only machine-readable surface reachable without credentials is the WordPress REST content API behind bluejaytx.com, catalogued here. That surface is notable for outliving the web site it belongs to: the marketing page tree was deleted in the teardown, but the REST API and the post archive still serve all 35 press releases and publication notices from 2021 through 2025 with full text.
Bluejay Therapeutics publishes 6 APIs on the APIs.io network, including Content API, Discovery API, Embed API, and 3 more. Tagged areas include Company, biopharmaceuticals, Pharmaceuticals, Life Sciences, and hepatology.
The Bluejay Therapeutics catalog on APIs.io includes 1 JSON-LD context.
Bluejay Therapeutics’ developer surface includes engineering blog, authentication, and 19 more developer resources.
What this lets a business do 1
Business capabilities this provider's published APIs can perform, derived from its own contracts. Browse all capabilities →
Kin Score
report_correction tool on the apis.io MCP.
APIs 6
Individual APIs this provider publishes, each with its own machine-readable definition.
Bluejay Therapeutics Content API
Posts, pages and cross-content search.
Bluejay Therapeutics Discovery API
Route index and namespace discovery documents.
Bluejay Therapeutics Embed API
oEmbed 1.0 provider endpoint.
Bluejay Therapeutics Empty Collections API
Registered collections that answer 200 anonymously but currently hold no items.
Bluejay Therapeutics Media API
The site media library.
Bluejay Therapeutics Taxonomy API
Categories, tags and taxonomy/type/status registries.
Open Collections 7
Open, tool-agnostic API collections (OpenAPI-derived and Bruno).
API Collection
OPEN COLLECTIONBluejay Therapeutics Content API
OPEN COLLECTIONBluejay Therapeutics Content Discovery API
OPEN COLLECTIONBluejay Therapeutics Content Embed API
OPEN COLLECTIONBluejay Therapeutics Content Empty Collections API
OPEN COLLECTIONBluejay Therapeutics Content Media API
OPEN COLLECTIONBluejay Therapeutics Content Taxonomy API
OPEN COLLECTIONScroll for all 7
Semantic Vocabularies 1
JSON-LD contexts and semantic vocabularies used across these APIs.
Security Posture 2
Authentication, domain security, vulnerability disclosure, and trust-center signals.
Resources
Agent Surfaces 3
MCP servers, agent skills, and machine-readable catalogs
Design & Contract 6
Pagination, idempotency, versioning, errors, and events
Access & Security 2
Authentication, authorization, and security posture
Company 4
The organization behind the API
Other 6
Properties that don't map to a standard resource type
Source (apis.yml)
Work with this as data
Every provider here is available over the APIs.io API and to AI agents over MCP.